Chi Pham, MD
Hematology & Oncology · Fort Worth, TXNPI 1881710226
Payments from drug & device makers
Across 360 payments — averaging $5547.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.4M
- Genentech, Inc.$430K
- AstraZeneca$97K
- GSK$68K
- Tesaro, Inc.$16K
- Viiv Healthcare Company$12K
- plus $4K from 32 others
Across 1 payment — averaging $28.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$28
What the payments were for
- Consulting fees$1,91041%
- Food & beverage$1,98043%
- Education$3217%
- Gifts$44510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 26 | $1,369,370 |
| Genentech, Inc. | 181 | $430,153 |
| AstraZeneca(2 entities) | 24 | $97,286 |
| GSK | 35 | $67,843 |
| Tesaro, Inc. | 1 | $16,068 |
| Viiv Healthcare Company | 3 | $11,859 |
| Puma Biotechnology, Inc. | 2 | $1,015 |
| Daiichi Sankyo Inc. | 3 | $955 |
| Novartis | 12 | $519 |
| Lilly USA, LLC | 9 | $326 |
| Caris MPI, Inc. | 3 | $154 |
| Seagen Inc. | 3 | $129 |
| Sirtex Medical Inc | 1 | $112 |
| Pfizer | 5 | $100 |
| Bristol Myers Squibb | 4 | $91 |
| Sanofi | 4 | $86 |
| Gilead(2 entities) | 4 | $83 |
| Incyte Corporation | 4 | $83 |
| Karyopharm Therapeutics Inc. | 4 | $76 |
| Johnson & Johnson | 4 | $71 |
| Stemline Therapeutics Inc. | 3 | $69 |
| Tempus AI, Inc | 3 | $67 |
| Genmab U.S., Inc. | 2 | $61 |
| Sobi, Inc | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| Amgen | 2 | $39 |
| AbbVie | 2 | $37 |
| Pharmaessentia USA Corporation | 1 | $34 |
| Novo Nordisk | 2 | $32 |
| Array Biopharma Inc | 1 | $30 |
| Morphosys, US Inc. | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| Merck | 1 | $19 |
| Bayer | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $18 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nerlynx$1,000
- MI CANCER SEEK$134
- KISQALI$130
- SIR-Spheres Microspheres$112
How this compares
$1,996,993 in reported general payments places this provider in the 90th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 23 | $528,804 |
| IbrancePalbociclib | 30 | $467,415 |
| VenclextaVenetoclax | 12 | $368,077 |
| DopteletAvatrombopag Maleate | 12 | $341,405 |
| ImbruvicaIbrutinib | 13 | $213,046 |
| NinlaroIxazomib Citrate | 12 | $143,507 |
| EliquisApixaban | 89 | $77,351 |
| ZarxioFilgrastim-Sndz | 11 | $27,963 |
| XareltoRivaroxaban | 24 | $13,137 |
| Anastrozole | 516 | $9,158 |
| VeozahFezolinetant | 15 | $8,911 |
| Exemestane | 38 | $6,636 |
| Cyclosporine | 14 | $4,814 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 122 | $4,587 |
| Letrozole | 146 | $3,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $100 | $544,765119 claims |
| AbbVieVenclexta | $37 | $368,07712 claims |
| Johnson & JohnsonXarelto | $71 | $13,13724 claims |
| Lilly USA, LLCOlanzapine | $326 | $4813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Fort Worth
- Robyn YoungFort Worth$4.9M
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
- Jorge Cortes-FrancoHouston$59.4M
- William WierdaHouston$58.7M
- Koji SasakiHouston$39.2M
- Kyriakos PapadopoulosSan Antonio$18.5M
- Loretta NastoupilHouston$18.3M
- Christopher FlowersHouston$17.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.